Inhibitex Awarded $489,000 in Grants under the Therapeutic Discovery Tax Credit Program
November 03 2010 - 10:39AM
Business Wire
Inhibitex, Inc. (NASDAQ: INHX) has been awarded approximately
$489,000 in grants under the Qualifying Therapeutic Discovery
Project ("QTDP") Program. This program was created under the
Patient Protection and Affordable Care Act of 2010 to provide tax
credits or grants representing up to 50 percent of eligible
qualified investments in therapeutic discovery projects during tax
years 2009 and 2010.
Inhibitex was awarded the grants for FV-100, which is in Phase
II clinical development for the treatment of shingles, and INX-189,
a nucleotide polymerase inhibitor in Phase 1b clinical development
for the treatment of chronic hepatitis C infections.
About Inhibitex
Inhibitex, Inc. is a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s clinical stage pipeline includes FV-100, a
bicyclic nucleoside inhibitor in Phase II development for the
treatment of shingles, and INX-189, a nucleotide polymerase
inhibitor in development for the treatment of chronic infections
caused by hepatitis C virus (HCV). The Company also has additional
HCV nucleotide polymerase inhibitors in various stages of
preclinical development and has licensed the use of its proprietary
MSCRAMM® protein platform to Pfizer for the development of active
staphylococcal vaccines. For additional information about the
Company, please visit www.inhibitex.com.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024